I. Introduction

59
Rapid diagnostic tests (RDTs) for infectious diseases have recently been implemented in 60 many laboratories and emergency departments (EDs) with the goal of expediting the 61 diagnosis of infectious diseases, infection prevention, appropriate initial management, and 62 to facilitate antimicrobial stewardship in the ED where rapid clinical decisions must be 63 undertaken in the context of overcrowding and time pressures [1] . Even though multiple 64
RDTs are currently available, their successful implementation in the ED requires careful 65 assessment of performance characteristics, potential benefits to patient care and cost 66 considerations, as well as a well-organized implementation plan to optimize their impact [2] . 67
The goal of this narrative review is to provide an overview of currently available RDTs for 68 infectious diseases in the ED with a detailed description of their performance and to discuss 69 their impact on patient care. 70
71
II. Methods
A comprehensive PubMed search was conducted through August 2019 to identify studies on 73
RDTs for infectious diseases in ED department using the following MeSH and keywords: 74 viruses and some atypical bacteria: Bordetella pertussis, Bordetella parapertussis, 150
Chlamydophila pneumoniae and Mycoplasma pneumoniae. Analytical performance 151 characteristics, compared to reference PCR assays, are good to excellent (sensitivity and 152 specificity from 80 to 100% for all targets). Of note, some bacterial targets have been 153 validated with fewer than 10 positive samples, and performance characteristics of bacterial 154 PCR have sometimes been reported to be lower than those of viral PCR [19] , highlighting the 155 need for caution when interpreting cumulative performance results. Furthermore, the 156 performance of some panels ( Table 1 ) only consist of percent agreement, which represents a 157 strong-and maybe underappreicated -limitation. 158
For the diagnosis of LRTIs in the ED, a short TAT is a key parameter for relevant therapeutic 159 measures, when targeted treatments and specific infection-prevention measures exist, such 160 as for RSV or influenza [62] . 161 162
II.3. Gastrointestinal (GI) infections
163
The rapid diagnosis of Clostridium difficile infection (CDI) is often based on a 2-or 3-stage 164 diagnostic approach using specific GDH antigen with enzyme immunoassays (EIA), 165 amplification of toxin A/B genes by PCR and detection of toxins A/B by EIA (Table 1) [39] † The performance characterisƟcs of the assays are described as sensiƟvity and specificity according to published clinical validation studies when available. In the absence of test comparison against a gold standard assay, the reported positive and negative percent agreement in the clinical studies reviewed were not reported to avoid any misinterpretation by the reader. * Sensitivity has been extracted from the "acute infection" population and specificity has been extracted from the "naïve individuals" population described in the corresponding reference. 
V. Conclusions
